• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Mesoblast Sees Path Forward for Twice-Rejected Cell Therapy After FDA Meeting

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 21, 2023 at 10:52: AM
via Following a Type A meeting with the FDA, Mesoblast claims it has a better understanding of what the regulator needs in order to consider approving remestemcel-L in the treatment of pediatric and adult steroid-refractory acute graft versus host disease, the company announced Thursday.

article source
 




Top Bottom
Back
Quote